Intuit Lifts FY Outlook, Shares Gain 9%

Shares of Intuit Inc. (INTU) jumped over 9% in extended trading session on Thursday after the accounting software maker lifted its outlook for the full year 2022.

Looking forward, the company now expects adjusted earnings of $11.48 to $11.64 per share and revenues of $12.165 billion to $12.300 billion.

Previously, the company expected adjusted earnings of $11.05 to $11.25 per share on revenue between $11.050 billion and $11.200 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $11.23 per share on revenues of $11.16 billion.

For the second quarter, the company expected adjusted earnings of $1.84 to $1.88 per share and revenue growth of about 73 to 74 percent. Analysts currently estimate earnings of $1.47 per share.

CEO Sasan Goodarzi said, "We continue to see strong momentum and proof that our Big Bets are further positioning us for durable growth in the future, and we're delighted that Mailchimp has joined Intuit."

INTU closed Thursday's trading at $628.94, down $6.12 or 0.96%, on the Nasdaq. The stock, however, gained $58.11 or 9.24% in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT